Literature DB >> 15474472

R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts.

Burkhard Hinz1, Robert Ramer, Karin Eichele, Ulrike Weinzierl, Kay Brune.   

Abstract

Cannabinoids induce the expression of the cyclooxygenase-2 (COX-2) isoenzyme in H4 human neuroglioma cells via a pathway independent of cannabinoid- or vanilloid receptor activation. The underlying mechanism was recently shown to involve increased synthesis of ceramide, which in turn leads to activation of p38 and p42/44 mitogen-activated protein kinases (MAPKs). The present study investigates a possible contribution of membrane lipid rafts to cannabinoid-induced COX-2 expression. To address this issue, we tested the influence of methyl-beta-cyclodextrin (MCD), a membrane cholesterol depletor, on COX-2 expression by the endocannabinoid analogue R(+)-methanandamide (R(+)-MA). Incubation of H4 cells with MCD was associated with a loss of lipid raft integrity and a substantial inhibition of R(+)-MA-induced COX-2 expression and subsequent formation of prostaglandin E2. Moreover, MCD was shown to suppress signal transduction steps upstream to COX-2 induction by R(+)-MA. Accordingly, the cholesterol depletor suppressed R(+)-MA-induced formation of ceramide as well as phosphorylation of p38 and p42/44 MAPKs. Together, our results suggest that R(+)-MA induces COX-2 expression in human neuroglioma cells via a pathway linked to lipid raft microdomains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15474472     DOI: 10.1016/j.bbrc.2004.09.095

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells.

Authors:  Moises Garcia-Arencibia; Eduardo Molina-Holgado; Francisco Molina-Holgado
Journal:  Br J Pharmacol       Date:  2018-06-22       Impact factor: 8.739

Review 2.  Cannabinoids and cancer: pros and cons of an antitumour strategy.

Authors:  Maurizio Bifulco; Chiara Laezza; Simona Pisanti; Patrizia Gazzerro
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

3.  R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells.

Authors:  Karin Eichele; Ulrike Weinzierl; Robert Ramer; Kay Brune; Burkhard Hinz
Journal:  Pharm Res       Date:  2006-11-08       Impact factor: 4.200

4.  Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats.

Authors:  S M Gardiner; J E March; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  2009-08-20       Impact factor: 8.739

Review 5.  Changes in the endocannabinoid system may give insight into new and effective treatments for cancer.

Authors:  Gianfranco Alpini; Sharon Demorrow
Journal:  Vitam Horm       Date:  2009       Impact factor: 3.421

6.  Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor.

Authors:  Li Huang; Jonathan C Ramirez; Gabriel A Frampton; Lessie E Golden; Matthew A Quinn; Hae Yong Pae; Darijana Horvat; Li-jian Liang; Sharon DeMorrow
Journal:  Lab Invest       Date:  2011-04-04       Impact factor: 5.662

7.  Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells.

Authors:  Monica Bari; Sergio Oddi; Chiara De Simone; Paola Spagnolo; Valeria Gasperi; Natalia Battista; Diego Centonze; Mauro Maccarrone
Journal:  Neuropharmacology       Date:  2007-07-20       Impact factor: 5.250

Review 8.  Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.

Authors:  Ken Soderstrom; Eman Soliman; Rukiyah Van Dross
Journal:  Front Pharmacol       Date:  2017-10-10       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.